NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children

Yang, Tianyou; Wen, Yang; Li, Jiahao; Tan, Tianbao; Yang, Jiliang; Pan, Jing; Hu, Chao; Yao, Yuxiao; Zhang, Jiao; Xin, Yijuan; Li, Suhong; Xia, Huimin; He, Jing; Zou, Yan

doi:10.1186/s40164-019-0135-z

Experimental Hematology & Oncology

Table 1 Association between hepatoblastoma risk and polymorphisms in NRAS and KRAS

From: NRAS and KRAS polymorphisms are not associated with hepatoblastoma susceptibility in Chinese children

Genotype	Patients (n = 213)	Controls (n = 958)	P ^a	Crude OR (95% CI)	P	Adjusted OR (95% CI)^b	P ^b
NRAS rs2273267 A > T (HWE = 0.794)
AA	103 (48.36)	486 (50.73)		1.00		1.00
AT	88 (41.31)	395 (41.23)		1.05 (0.77–1.44)	0.755	1.05 (0.77–1.44)	0.758
TT	22 (10.33)	77 (8.04)		1.35 (0.80–2.27)	0.259	1.35 (0.80–2.27)	0.259
Additive			0.528	1.12 (0.89–1.40)	0.338	1.12 (0.89–1.40)	0.338
Dominant	110 (51.64)	472 (49.27)	0.531	1.10 (0.82–1.48)	0.531	1.10 (0.82–1.48)	0.532
Recessive	191 (89.67)	881 (91.96)	0.277	1.32 (0.80–2.17)	0.278	1.32 (0.80–2.17)	0.277
KRAS rs12587 G > T (HWE = 0.132)
GG	128 (60.09)	609 (63.57)		1.00		1.00
GT	79 (37.09)	300 (31.32)		1.25 (0.92–1.71)	0.158	1.26 (0.92–1.72)	0.155
TT	6 (2.82)	49 (5.11)		0.58 (0.24–1.39)	0.223	0.58 (0.24–1.39)	0.223
Additive			0.130	1.04 (0.80–1.34)	0.789	1.04 (0.80–1.34)	0.788
Dominant	85 (39.91)	349 (36.43)	0.342	1.16 (0.86–1.57)	0.342	1.16 (0.86–1.57)	0.341
Recessive	207 (97.18)	909 (94.89)	0.152	0.54 (0.23–1.27)	0.158	0.54 (0.23–1.27)	0.158
KRAS rs7973450 A > G (HWE = 0.213)
AA	178 (83.57)	798 (83.30)		1.00		1.00
AG	35 (16.43)	156 (16.28)		1.01 (0.67–1.50)	0.977	1.01 (0.67–1.50)	0.979
GG	0 (0.00)	4 (0.42)		/	/	/	/
Additive			0.640	0.95 (0.65–1.41)	0.814	0.95 (0.65–1.41)	0.811
Dominant	35 (16.43)	160 (16.70)	0.924	0.98 (0.66–1.46)	0.924	0.98 (0.66–1.46)	0.921
Recessive	213 (100.00)	954 (99.58)	0.345	/	/	/	/
KRAS rs7312175 G > A (HWE = 0.300)
GG	167 (78.40)	740 (77.24)		1.00		1.00
GA	44 (20.66)	200 (20.88)		0.98 (0.68–1.41)	0.892	0.98 (0.68–1.41)	0.892
AA	2 (0.94)	18 (1.88)		0.49 (0.11–2.14)	0.345	0.49 (0.11–2.15)	0.345
Additive			0.626	0.91 (0.65–1.26)	0.553	0.91 (0.65–1.26)	0.554
Dominant	46 (21.60)	218 (22.76)	0.714	0.94 (0.65–1.34)	0.714	0.94 (0.65–1.34)	0.715
Recessive	211 (99.06)	940 (98.12)	0.338	0.50 (0.11–2.15)	0.348	0.50 (0.11–2.15)	0.348
Combined effect of protective genotypes^c
0	139 (65.26)	605 (63.15)		1.00		1.00
1	63 (29.58)	303 (31.63)		0.91 (0.65–1.26)	0.551	0.91 (0.65–1.26)	0.552
2	9 (4.23)	26 (2.71)		1.51 (0.69–3.29)	0.303	1.51 (0.69–3.29)	0.302
3	2 (0.94)	24 (2.51)		0.36 (0.09–1.55)	0.172	0.36 (0.09–1.55)	0.172
Trend			0.306	0.92 (0.73–1.16)	0.458	0.92 (0.73–1.16)	0.458
0	139 (65.26)	605 (63.15)		1.00		1.00
1–3	74 (34.74)	353 (36.85)	0.564	0.91 (0.67–1.25)	0.564	0.91 (0.67–1.25)	0.561

OR odds ratio, CI confidence interval, HWE Hardy–Weinberg equilibrium
^aBy χ² test vs. cancer-free controls
^bAdjusted for age and gender
^cRisk genotypes are rs12587 TT, rs7973450 AG/GG, and rs7312175 GA/AA

Back to article page

ISSN: 2162-3619

Contact us

Submission enquiries: journalsubmissions@springernature.com